[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-335651-105":59,"doc-detail-335651-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","emerging-functions-of-fmnl1-in-myeloid-neoplasms-insights-from-bioinformatics-to-biological-and-pharmacological-landscapes","Emerging functions of FMNL1 in myeloid neoplasms - insights from bioinformatics to biological and pharmacological landscapes","","Myeloid neoplasms involve abnormal proliferation and differentiation of myeloid cells, including MDS, MPN, AML, and CML. Formin-like protein 1 (FMNL1), a regulator of the actin cytoskeleton predominantly expressed in hematopoietic cells, is investigated for its role in leukemia biology. Using public transcriptomic resources, cell-line experiments, TCGA RNA-seq analysis, and drug-sensitivity predictions from Beat AML and GDSC, the study links FMNL1 expression patterns to differentiation, signaling, immune activity, and potential therapeutic relevance in AML.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/emerging-functions-of-fmnl1-in-myeloid-neoplasms-insights-from-bioinformatics-to-biological-and-pharmacological-landscapes/335651/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/emerging-functions-of-fmnl1-in-myeloid-neoplasms-insights-from-bioinformatics-to-biological-and-pharmacological-landscapes/335651.png","ImageObject",300,407,{"name":92,"@type":93},"Clementine","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main purpose of studying FMNL1 in myeloid neoplasms?","Question",{"text":112,"@type":113},"The study examines FMNL1 expression in normal hematopoiesis and myeloid neoplasms and evaluates links to clinical-laboratory features, mutational status, survival outcomes, and drug sensitivity in AML.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does FMNL1 expression relate to cell differentiation in the results?",{"text":117,"@type":113},"FMNL1 is highly expressed in metamyelocytes, neutrophils, and monocytes, and its expression increases with granulocytic differentiation.",{"name":119,"@type":110,"acceptedAnswer":120},"Does FMNL1 expression show associations with survival outcomes in AML?",{"text":121,"@type":113},"FMNL1 expression is not significantly associated with clinical-laboratory characteristics or survival outcomes, but it is associated with a higher frequency of WT1 mutations when FMNL1 expression is low in AML patients.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},335651,1790062774,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":4},1374391974564,"https://ap-avatar.wpscdn.com/avatar/14000253aa45c000a9e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779874745381141002","Emerging functions of FMNL1 in myeloid neoplasms: insights from bioinformatics to biological and pharmacological landscapes  \nJoão Agostinho Machado-Neto1^, Hugo Passos Vicari1^, Jean Carlos Lipreri da Silva1^, Maria Fernanda Lopes Carvalho1^, Keli Lima1,2^  \n1Department of Pharmacology, Institute of Biomedical Sciences, University of São Paulo (USP), São Paulo, Brazil; 2Laboratory of Medical Investigation in Pathogenesis and Targeted Therapy in Onco-Immuno-Hematology (LIM-31), Division of Hematology, Department of Internal Medicine, Medical School, University of São Paulo, São Paulo, Brazil  \nContributions: (I) Conception and design: JA Machado-Neto, K Lima; (II) Administrative support: JA Machado-Neto; (III) Provision of study materials or patients: JA Machado-Neto, K Lima; (IV) Collection and assembly of data: All authors; (V) Data analysis and interpretation: All authors;  \n(VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.  \nCorrespondence to: João Agostinho Machado-Neto, PhD. Department of Pharmacology, Institute of Biomedical Sciences, University of São Paulo  \n(USP), Av. Prof. Lineu Prestes, 1524, CEP 05508-900 São Paulo, [Brazil. Email: jamachadoneto@usp.br](Brazil. Email: jamachadoneto@usp.br).  \nBackground: Myeloid neoplasms encompass disorders characterized by abnormal myeloid cell proliferation and differentiation, including myelodysplastic syndromes (MDS), myeloproliferative neoplasms, acute myeloid leukemia (AML), and chronic myeloid leukemia (CML) . Formin-like protein 1 (FMNL1) is involved in the regulation of the actin cytoskeleton and is predominantly expressed in hematopoietic cells.  \nGiven its role in leukemia cell proliferation, survival, migration, and invasion, this study investigates FMNL1 expression in normal hematopoiesis and myeloid neoplasms and explores associations with clinical-laboratory  \ncharacteristics, mutational status, and survival outcomes in AML.  \nMethods: Transcript levels ofFMNL1 from several blood-forming cell populations and myeloid neoplasms were extracted from publicly available databases. Myeloid neoplasm cell lines were used for gene/protein expression and cell differentiation studies. Functional genomics analysis was performed using RNA-seq data from The Cancer Genome Atlas (TCGA) AML study, and drug sensitivity predictions were investigated using Beat AML and Genomics of Drug Sensitivity in Cancer (GDSC) datasets. Statistical analyses assessed  \nthe impact ofFMNL1 expression on clinical outcomes.  \nResults: FMNL1 was highly expressed in metamyelocytes, neutrophils, and monocytes compared to hematopoietic stem cells, and its expression increased with granulocytic differentiation. FMNL1 expression was elevated in AML and CML patients compared to healthy donors. FMNL1 expression was not significantly associated with clinical-laboratory characteristics or survival outcomes but showed a higher frequency of WT1 transcription factor (WT1) mutations with low FMNL1 expression in AML patients.  \nHigh FMNL1 expression in AML correlated with immune response and inflammatory activity pathways.  \nFMNL1 mRNA levels influenced drug sensitivity in AML models, with correlations observed for specific  \nantineoplastic agents.  \nConclusions: FMNL1 plays a potential role in granulocyte differentiation and function, and its differential expression is linked to critical signaling pathways in leukemogenesis and inflammation. These findings highlight FMNL1’s potential therapeutic implications in myeloid neoplasia, warranting further investigation.  \nKeywords: Myeloid neoplasms; formin-like protein 1 (FMNL1); acute myeloid leukemia (AML); bioinformatics;  \nfunctional genomics  \n^ ORCID: João Agostinho Machado-Neto, 0000-0002-2937-8109; Hugo Passos Vicari, 0000-0001-6121-3315; Jean Carlos Lipreri da Silva, 0000-0002-2569-5959; Maria Fernanda Lopes Carvalho, 0000-0002-9712-6050; Keli Lima, 0000-0002-5498-7539.  \n© AME Publishing Company. Transl Cancer Res 2024;13(11):","cbCaiqXUGSFXUn9w","https://ap.wps.com/l/cbCaiqXUGSFXUn9w","pdf",6262331,12,"English","# Introduction\n## Background on myeloid neoplasms and FMNL1\n# Methods\n## Data sources and functional genomics workflow\n# Results\n## Expression patterns, mutation associations, and pathways\n# Conclusions","[{\"question\":\"What is the main purpose of studying FMNL1 in myeloid neoplasms?\",\"answer\":\"The study examines FMNL1 expression in normal hematopoiesis and myeloid neoplasms and evaluates links to clinical-laboratory features, mutational status, survival outcomes, and drug sensitivity in AML.\"},{\"question\":\"How does FMNL1 expression relate to cell differentiation in the results?\",\"answer\":\"FMNL1 is highly expressed in metamyelocytes, neutrophils, and monocytes, and its expression increases with granulocytic differentiation.\"},{\"question\":\"Does FMNL1 expression show associations with survival outcomes in AML?\",\"answer\":\"FMNL1 expression is not significantly associated with clinical-laboratory characteristics or survival outcomes, but it is associated with a higher frequency of WT1 mutations when FMNL1 expression is low in AML patients.\"}]","Emerging functions of FMNL1 in myeloid neoplasms - insights from bioinformatics to biological and pharmacological landscapes | PDF",1790011837]